Galectin Therapeutics, Inc. (GALT) EPS Estimated At $-0.10

October 13, 2018 - By Ellis Scott

Galectin Therapeutics, Inc. (NASDAQ:GALT) LogoInvestors sentiment decreased to 1.5 in 2018 Q2. Its down 0.36, from 1.86 in 2018Q1. It fall, as 7 investors sold Galectin Therapeutics, Inc. shares while 11 reduced holdings. 13 funds opened positions while 14 raised stakes. 4.60 million shares or 14.35% more from 4.02 million shares in 2018Q1 were reported.
Dynamic Advisor Solutions, Arizona-based fund reported 10,000 shares. Susquehanna Int Grp Llp holds 0% or 357,793 shares in its portfolio. Cwm Limited Liability Company invested in 2,000 shares or 0% of the stock. Bank & Trust Of Montreal Can holds 0% or 75,500 shares in its portfolio. State Bank Of Mellon reported 0% stake. Sabby Ltd Company stated it has 14,029 shares. Deutsche Bancorp Ag accumulated 0% or 1,302 shares. Da Davidson & reported 656,527 shares or 0.08% of all its holdings. Vanguard Gru Inc stated it has 1.21M shares. First Allied Advisory Services has invested 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Tci Wealth Advsrs has invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Royal Bank & Trust Of Canada holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 1,600 shares. Lpl Llc owns 30,793 shares for 0% of their portfolio. Buckingham Asset Mngmt Ltd owns 10,000 shares. Northern Tru Corporation has 86,618 shares for 0% of their portfolio.

Since April 16, 2018, it had 1 insider purchase, and 23 selling transactions for $14.94 million activity. CZIRR JAMES C sold $1.49M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Wednesday, June 13. Another trade for 226,000 shares valued at $1.95M was sold by CALLICUTT JACK W. The insider 10X Fund – L.P. sold 50,000 shares worth $256,081. Another trade for 119,200 shares valued at $602,920 was sold by Shlevin Harold H.. ZUCCONI THEODORE DANIEL also sold $14,320 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Monday, April 16. TRABER PETER G sold $409,997 worth of stock.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.10 EPS on November, 6.They anticipate $0.03 EPS change or 23.08 % from last quarter’s $-0.13 EPS. After having $-0.11 EPS previously, Galectin Therapeutics, Inc.’s analysts see -9.09 % EPS growth. The stock increased 1.22% or $0.06 during the last trading session, reaching $4.99. About 227,705 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 208.00% since October 14, 2017 and is uptrending. It has outperformed by 192.38% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $204.16 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin up 11% premarket on positive early-stage data on GR-MD-02 in melanoma” on September 20, 2018. Also published the news titled: “Your Cancer Highlight: Galectin Surprises With Early-Stage Collaborative Data” on September 21, 2018.‘s news article titled: “Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock?” with publication date: September 18, 2018 was also an interesting one.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.